Bionano Genomics, Inc. (BNGO): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama en rápida evolución de la investigación genómica, Bionano Genomics (BNGO) surge como una fuerza transformadora, revolucionando nuestra comprensión del mapeo genético a través de su tecnología de mapeo de genoma óptico de vanguardia. Al cerrar la innovación científica avanzada con soluciones de diagnóstico prácticas, la compañía ha desarrollado un modelo de negocio sofisticado que capacita a los investigadores, médicos y profesionales de biotecnología para desbloquear ideas sin precedentes sobre estructuras genéticas y posibles marcadores de enfermedades. Esta exploración completa del lienzo de modelo de negocio de Bionao Genomics revela un enfoque estratégico que posiciona a la compañía a la vanguardia del análisis genómico, ofreciendo la detección de variantes estructurales de alta resolución y las soluciones tecnológicas rentables que están rehaporando el futuro de la investigación genética y los diagnósticos clínicos.

Bionano Genomics, Inc. (BNGO) - Modelo de negocios: asociaciones clave

Colaboración con instituciones de investigación académica

A partir de 2024, Bionano Genomics ha establecido asociaciones con las siguientes instituciones académicas:

Institución	Enfoque de colaboración	Año establecido
Universidad de Stanford	Investigación genómica	2022
Escuela de Medicina de Harvard	Investigación citogenética	2023
Universidad de California, San Diego	Mapeo del genoma óptico	2021

Asociaciones estratégicas con centros de investigación genómica

Bionano Genomics ha desarrollado asociaciones estratégicas con los siguientes centros de investigación genómica:

• Instituto Nacional de Investigación del Genoma Humano (NHGRI)
• Genómica Inglaterra
• Mayo Clinic Genome Center

Acuerdos con laboratorios de diagnóstico clínico

Asociaciones de laboratorio de diagnóstico clínico a partir de 2024:

Laboratorio	Tipo de asociación	Región geográfica
Diagnóstico de misiones	Integración de la plataforma de prueba	Estados Unidos
Laboratorios ARUP	Implementación del mapeo del genoma óptico	Estados Unidos
Atención médica sonora	Colaboración tecnológica	Global

Relaciones con compañías farmacéuticas y de biotecnología

Asociaciones clave de la empresa farmacéutica y de biotecnología:

• Illumina, Inc.
• Roche Diagnostics
• Thermo Fisher Scientific
• Novartis Pharmaceuticals

Colaboraciones de asociación total: 12 asociaciones confirmadas en sectores de investigación, clínicos y farmacéuticos a partir de 2024.

Bionano Genomics, Inc. (BNGO) - Modelo de negocio: actividades clave

Desarrollo de la tecnología de mapeo del genoma óptico

Bionano Genomics se centra en desarrollar el sistema de mapeo del genoma óptico SAPHYR® con las siguientes especificaciones clave:

• Capacidad de resolución: detectar variaciones estructurales de hasta 10 kilobases
• Rendimiento de imágenes: 250 GB por ejecución
• Tiempo de procesamiento de la muestra: aproximadamente 3-4 horas por genoma

Investigación e innovación de productos en análisis genómico

Área de investigación	Inversión (2023)	Enfocar
Variación estructural genómica	$ 12.4 millones	Genómica del cáncer, diagnóstico de enfermedades raras
Desarrollo de algoritmo de software	$ 7.2 millones	Precisión de mapeo del genoma mejorado

Fabricación de sistemas de mapeo genómico

Métricas de producción para sistemas Saphyr® en 2023:

• Sistemas totales fabricados: 87 unidades
• Costo promedio de producción por sistema: $ 250,000
• Ubicaciones de fabricación: San Diego, California

Desarrollo de software clínico y científico

Plataforma de software	Costo de desarrollo	Base de usuarios
Software Bionano Solve ™	$ 5.6 millones	Más de 250 instituciones de investigación
Tubería de análisis del genoma	$ 3.9 millones	Laboratorios de diagnóstico clínico

Mejora y validación tecnológica continua

Métricas de mejora de la tecnología para 2023:

• Gasto de I + D: $ 24.1 millones
• Solicitudes de patentes presentadas: 12
• Publicaciones científicas: 37 artículos revisados ​​por pares

Bionano Genomics, Inc. (BNGO) - Modelo de negocios: recursos clave

Plataforma de mapeo de genoma óptico avanzado

El sistema Saphyr de Bionano Genomics representa su recurso tecnológico central. A partir del cuarto trimestre de 2023, la compañía informó:

• Base total instalada de 245 sistemas Saphyr a nivel mundial
• Costo promedio del sistema: $ 350,000 por unidad
• Ingresos del contrato de mantenimiento: $ 75,000 anuales por sistema

Equipo de Investigación e Ingeniería Genómica Especializada

Categoría de empleado	Número	Porcentaje
Total de empleados	271	100%
Personal de I + D	127	46.9%
Personal de ingeniería	83	30.6%

Software de mapeo y visualización genómico patentado

Los recursos de software incluyen:

• Software de análisis del genoma de Saphyr
• Plataforma de nube de Bionano Access
• Herramientas bioinformáticas integradas

Cartera de propiedades intelectuales

Categoría de IP	Recuento total
Patentes emitidos	37
Aplicaciones de patentes pendientes	22
Activos totales de IP	59

Investigación avanzada y instalaciones de fabricación

Detalles de la instalación:

• Ubicación principal: San Diego, California
• Espacio total de la instalación: 45,000 pies cuadrados
• Capacidad de fabricación: 60 sistemas Saphyr por trimestre

Bionano Genomics, Inc. (BNGO) - Modelo de negocio: propuestas de valor

Detección de variante estructural de alta resolución

Bionano Genomics ofrece tecnología de mapeo óptico del genoma (OGM) con las siguientes especificaciones:

Parámetro tecnológico	Especificación
Resolución de mapeo del genoma	Detección de variante estructural de hasta 250 kb
Precisión de mapeo	99.91% de precisión
Tiempo de procesamiento de muestras	24-48 horas

Soluciones integrales de mapeo del genoma

Las soluciones genómicas clave incluyen:

• Sistema Saphyr para el mapeo del genoma
• Análisis de enfermedad constitucional rara
• Perfil genómico del cáncer
• Investigación genómica agrícola

Tecnología de análisis genómico rentable

Métrico de costo	Valor
Por costo de mapeo del genoma	Aproximadamente $ 1,000- $ 1,500
Costo comparativo de secuenciación tradicional	$3,000-$5,000

Capacidades de diagnóstico mejoradas para los trastornos genéticos

Métricas de rendimiento de diagnóstico:

• Detección de variaciones estructurales complejas
• Identificación de reordenamientos cromosómicos
• Precisión de detección del trastorno genético: 97.5%

Investigación mejorada y herramientas de toma de decisiones clínicas

Aplicación de investigación	Capacidad
Instituciones de investigación clínica utilizando tecnología	Más de 250 instituciones globales
Documentos de investigación publicados	Más de 500 publicaciones revisadas por pares

Bionano Genomics, Inc. (BNGO) - Modelo de negocios: relaciones con los clientes

Soporte técnico para la investigación y los usuarios clínicos

Bionano Genomics proporciona soporte técnico dedicado a través de múltiples canales:

Canal de soporte	Tiempo de respuesta	Disponibilidad
Soporte por correo electrónico	24-48 horas	De lunes a viernes de 8 a.m. a 6 p.m. PST
Soporte telefónico	Inmediato	De lunes a viernes de 9 a.m. a 5 p.m. PST
Sistema de boletos en línea	72 horas máximo	Sumisión 24/7

Asistencia de capacitación e implementación

Los servicios de capacitación del cliente incluyen:

• Capacitación técnica en el sitio
• Instrucción basada en seminarios web
• Manuales de usuario completos
• Biblioteca de video tutorial

Actualizaciones regulares de software y tecnología

Actualización de frecuencia	Tipo de actualizaciones	Método de notificación
Trimestral	Parches de software	Notificaciones por correo electrónico
By-anualmente	Versiones principales de software	Comunicación directa del cliente

Centro de recursos y portal de clientes en línea

Características del portal de clientes de Bionano Genomics:

• Seguimiento de rendimiento del instrumento en tiempo real
• Herramientas de gestión de datos
• Repositorio de documentación técnica
• Foros de discusión comunitaria

Servicios de consulta personalizados

Tipo de consulta	Duración	Público objetivo
Consulta de estrategia de investigación	1-2 horas	Investigadores académicos
Taller de implementación clínica	Medio día	Profesionales de laboratorio clínico
Diseño de flujo de trabajo personalizado	Múltiples sesiones	Grandes instituciones de investigación

Bionano Genomics, Inc. (BNGO) - Modelo de negocios: canales

Equipo de ventas directo dirigido a instituciones de investigación

Bionano Genomics mantiene un equipo de ventas directo dedicado centrado en las instituciones de investigación. A partir del cuarto trimestre de 2023, la compañía reportó 47 representantes de ventas directas dirigidas a centros de investigación académica, centros de genoma y laboratorios clínicos.

Tipo de canal de ventas	Segmento objetivo	Número de representantes
Equipo de ventas directas	Instituciones de investigación	47

Plataforma de productos y servicios en línea

La compañía opera una plataforma en línea integral para pedidos de productos y soporte técnico. En 2023, la plataforma digital procesó aproximadamente 1,285 pedidos de productos y solicitudes de servicio.

Métricas de plataforma digital	2023 rendimiento
Pedidos de productos	872
Solicitudes de servicio	413
Transacciones digitales totales	1,285

Conferencias científicas y eventos de la industria

Bionano Genomics participa activamente en conferencias científicas para mostrar sus tecnologías. En 2023, la compañía asistió a 18 principales conferencias genómicas a nivel mundial.

• Reunión anual de la Sociedad Americana de Genética Humana
• Conferencia europea de genética humana
• Planta internacional & Conferencia del genoma animal

Seminarios web y marketing digital

La compañía realizó 24 seminarios web en 2023, llegando a aproximadamente 3.650 participantes profesionales en la investigación y los dominios clínicos.

Métricas de compromiso digital	2023 datos
Total de seminarios web	24
Participantes de seminarios web	3,650

Asociaciones con distribuidores científicos

Bionano Genomics colabora con 12 socios de distribución científica para expandir su alcance del mercado global. Estas asociaciones cubren las regiones de América del Norte, Europa y Asia-Pacífico.

Regiones de distribución de socios	Número de socios
América del norte	5
Europa	4
Asia-Pacífico	3
Socios de distribución total	12

Bionano Genomics, Inc. (BNGO) - Modelo de negocios: segmentos de clientes

Instituciones de investigación académica

A partir de 2024, Bionano Genomics se dirige a las instituciones de investigación académica con su sistema de mapeo del genoma Saphyr. Aproximadamente 1.237 universidades de investigación globalmente utilizan tecnologías genómicas avanzadas.

Tipo de cliente	Penetración estimada del mercado	Gasto anual en tecnologías genómicas
Universidades de investigación de primer nivel	62%	$ 3.4 millones
Universidades de investigación de nivel medio	38%	$ 1.2 millones

Laboratorios de diagnóstico clínico

Los laboratorios de diagnóstico clínico representan un segmento crítico de clientes para Bionano Genomics.

• Número total de laboratorios de diagnóstico clínico en los Estados Unidos: 8,700
• Tasa de adopción del mercado estimada para la tecnología Saphyr: 17.3%
• Inversión anual promedio en tecnologías de diagnóstico genómico: $ 875,000

Organizaciones de investigación farmacéutica

Las compañías farmacéuticas utilizan las tecnologías de mapeo genómico de Bionano para el desarrollo e investigación de medicamentos.

Tamaño de la empresa	Número de clientes potenciales	Inversión tecnológica promedio
Grandes compañías farmacéuticas	47	$ 5.6 millones
Compañías farmacéuticas de tamaño mediano	126	$ 2.3 millones

Centros de prueba genéticos

Los centros de pruebas genéticas representan un segmento de clientes creciente para Bionano Genomics.

• Centros de pruebas genéticas totales en América del Norte: 2,340
• Porcentaje utilizando tecnologías avanzadas de mapeo del genoma: 24.6%
• Presupuesto anual de tecnología genómica: $ 650,000

Compañías de biotecnología

Las empresas de biotecnología son clientes clave para las soluciones de mapeo genómico de Bionano Genomics.

Segmento de biotecnología	Número de clientes potenciales	Tasa de adopción de tecnología
Biotecnología centrada en la genómica	213	42.7%
Desarrollo terapéutico Biotecnología	356	29.4%

Bionano Genomics, Inc. (BNGO) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Bionano Genomics informó gastos de I + D de $ 39.7 millones, lo que representa una inversión significativa en el desarrollo de tecnología genómica.

Año fiscal	Gastos de I + D	Porcentaje de ingresos
2023	$ 39.7 millones	70.5%
2022	$ 44.1 millones	75.3%

Costos de fabricación y producción

Bionano Genomics incurre en los costos de fabricación relacionados principalmente con su sistema de mapeo de genoma óptico Saphyr y consumibles.

• Costo de ingresos para 2023: $ 16.4 millones
• Margen bruto: 51.3%
• Sobrecoss de fabricación: aproximadamente $ 5.2 millones anuales

Inversiones de ventas y marketing

Los gastos de ventas y marketing para Bionano Genomics en 2023 totalizaron $ 22.3 millones.

Categoría de gastos	Cantidad	Porcentaje de ingresos
Personal de ventas	$ 12.6 millones	35.7%
Programas de marketing	$ 9.7 millones	27.5%

Adquisición de personal y talento

Los gastos operativos totales relacionados con el personal para 2023 fueron de $ 78.2 millones.

• Total de empleados: 283 al 31 de diciembre de 2023
• Compensación promedio por empleado: $ 276,000
• Compensación basada en acciones: $ 15.3 millones

Mantenimiento de la infraestructura tecnológica

Costos de tecnología e infraestructura para mantener plataformas de investigación genómica y sistemas computacionales.

Componente de infraestructura	Costo anual
Sistemas de TI	$ 3.6 millones
Computación en la nube	$ 2.1 millones
Licencias de software	$ 1.5 millones

Bionano Genomics, Inc. (BNGO) - Modelo de negocios: flujos de ingresos

Venta de sistemas de mapeo genómico

A partir del cuarto trimestre de 2023, Bionano Genomics informó las siguientes ventas del sistema:

Tipo de sistema	Precio medio	Unidades vendidas en 2023
Sistema saphyr	$375,000	39 sistemas

Tasas de licencia de software recurrentes

Bionano Genómica generada $ 4.1 millones en ingresos de software y servicio para el año fiscal 2023.

Contratos de servicio y soporte técnico

Tipo de servicio	Ingresos anuales
Contratos de servicio anuales	$ 2.3 millones
Acuerdos de soporte técnico	$ 1.8 millones

Acuerdos de investigación colaborativos

En 2023, Bionano informó $ 3.5 millones de colaboraciones de investigación, incluido:

• Proyectos de investigación financiados por NIH
• Acuerdos de asociación farmacéutica
• Colaboraciones de investigación académica

Ventas de consumibles y reactivos

Categoría de productos	Ingresos anuales
Reactivos de mapeo óptico	$ 7.2 millones
Kits de consumo	$ 5.6 millones

Ingresos totales de la compañía para el año fiscal 2023: $ 24.5 millones

Bionano Genomics, Inc. (BNGO) - Canvas Business Model: Value Propositions

Superior detection of structural variants (SVs) down to 500 bp, often missed by NGS. In a comparative study for acute leukemia, Optical Genome Mapping (OGM) uniquely found 37 events, representing 15.8% of positive findings, while both OGM and targeted RNA-seq detected 175 events (74.7% of positives).

Consolidates multiple traditional cytogenetics tests into a single digital workflow. This consolidation is supported by the establishment of a new Category I Current Procedural Terminology (CPT) code by the American Medical Association for OGM use in cytogenomic genome-wide analysis for constitutional genetic disorders. Furthermore, the final 2026 Clinical Lab Fee Schedule indicates a 47% Increase in Payment Determination for the Category I CPT code for OGM use in Hematologic Malignancies.

High-resolution, genome-wide structural variation analysis for complex diseases. The technology's utility is demonstrated by the growing body of research, with 97 new peer-reviewed publications in Q3 2025, a 10% increase year-over-year. During that same quarter, 841 human clinical research genomes were published using OGM, marking an 84% increase compared to Q3 2024.

Faster workflow from sample to SV call, in as little as three days.

Platform-agnostic software for integrated analysis of OGM, NGS, and microarray data. The VIA software, in its latest version 7.2, automates variant calling, annotation, and interpretation with Artificial Intelligence for enhanced contextualization across OGM, microarray, and next-generation sequencing (NGS) data.

The adoption and utilization metrics for the platform as of late 2025 reflect the value proposition's traction:

Metric	Q3 2025 Value	Q2 2025 Value	Year-over-Year Change (Q3 vs Q3 2024)
Installed OGM System Base	384 systems	378 systems	4% increase (Q3 2025 vs Q3 2024)
Nanochannel Array Flowcells Sold	8,390 units	7,233 units	7% increase
Consumables and Software Revenue Growth	N/A	16% increase (Q2 2025 vs Q2 2024)	15% increase (Q3 2025 vs Q3 2024)

The focus on routine users drives recurring revenue, as seen in the non-GAAP gross margin expansion:

• Non-GAAP Gross Margin in Q3 2025: 46%.
• Non-GAAP Gross Margin in Q2 2025: 52%.
• Non-GAAP Gross Margin in Q3 2024: 26%.

Bionano Genomics, Inc. (BNGO) - Canvas Business Model: Customer Relationships

You're focused on driving utilization from the established user base, which is the core of the current relationship strategy for Bionano Genomics, Inc. (BNGO). This approach centers on supporting and deepening engagement with the specific customers already running Optical Genome Mapping (OGM) systems.

The company's strategy explicitly targets sustaining and supporting its base of 118 routine use customers. These core accounts are critical, as they accounted for over 80% of consumables revenue as of late 2024, a focus that continued into 2025. This emphasis on existing users is showing results in utilization metrics; for instance, flow cell purchases by these existing customers grew by 7% in the first nine months of 2025 compared to the same period a year ago. The total installed base stood at 384 OGM systems at the end of the third quarter of 2025.

Bionano Genomics, Inc. (BNGO) supports these relationships with dedicated service infrastructure. The Saphyr™ Assure Service provides an optional (opt-in) automated health monitoring feature that continuously inspects data quality and instrument performance, allowing Bionano Support to proactively repair systems with minimal downtime. This service is key for maintaining the uptime of the installed base, which saw 7 new OGM systems installed in the third quarter of 2025 alone, contributing to a year-to-date total of 23 new system installations, with expectations to surpass 25 for the full year 2025.

Scientific and educational engagement builds the community around the technology. The company supports this through direct engagement and publication metrics.

• OGM users worldwide have published on a cumulative basis nearly 11,500 clinical research genomes.
• In the third quarter of 2025, there were 97 new publications demonstrating the value of OGM, representing a 10% growth over the same period the year before.
• Over 500 publications cite OGM solutions in total.

The direct sales and support model is geared toward these high-volume, routine-use clinical and research labs. The success of this relationship focus is reflected in the Q3 2025 financial performance, where total revenue reached $7.4 million, with consumables and software revenues increasing by 15% year-over-year. The company sold 8,390 nanochannel array flowcells in that quarter.

Here's a quick look at the utilization and installed base metrics as of the end of Q3 2025:

Metric	Value	Period/Context
Routine Use Customers Supported	118	Core revenue driver focus
Flowcells Sold	8,390 units	Q3 2025
Total Installed Base	384 systems	End of Q3 2025
New Systems Installed	7 units	Q3 2025
Consumables & Software Revenue Growth	15%	Q3 2025 vs Q3 2024

The ongoing support structure, including dedicated Field Applications and Field Service teams, is essential for onboarding and sustaining these labs, ensuring they can effectively use the system for routine analysis.

Bionano Genomics, Inc. (BNGO) - Canvas Business Model: Channels

You're looking at how Bionano Genomics, Inc. gets its Optical Genome Mapping (OGM) technology and data analysis tools into the hands of researchers and clinicians as of late 2025. The core strategy has definitely shifted to driving utilization from a focused group, so the channel mix reflects that intensity.

The direct sales force remains key, targeting what management calls its core group of 118 routine use customers, which, as of late 2024, accounted for over 80% of consumables revenue. This direct engagement helps push adoption in core geographies where the Americas region saw revenue increase by 9% year-over-year and EMEA sales rose by 10% in the full year 2024. That's how they are managing the near-term growth while keeping costs down.

For international reach beyond those core areas, Bionano Genomics relies on third-party distributors. The company supports its worldwide audiences through these partners, with specific mentions of activity in regions like North China (via Ecobono), Taiwan (via Pharmigene, Inc.), Thailand (via MDx Thailand), and Colombia (via Rochem Biocare S.A.S). Management also highlighted global momentum, noting research activity in regions like Japan, though specific distributor-driven revenue figures aren't broken out.

Online access is a growing channel, intrinsically linked to the installed base. The company is focused on driving utilization of its VIA software, which saw its segment grow by 11% in fiscal year 2024. In the third quarter of 2025, the combined consumables and software revenue was a strong $5.3 million out of the total reported revenue of $7.4 million for that quarter. This shows the digital component is a major revenue driver now.

Here's a quick look at how the revenue mix broke down in Q3 2025, showing the shift to recurring revenue streams:

Revenue Component	Q3 2025 Amount	Year-over-Year Growth (Q3 2025 vs Q3 2024)
Total Revenue	$7.4 million	21% increase
Consumables and Software Revenue	$5.3 million	15% increase
Nanochannel Array Flowcells Sold	8,390 units	7% increase
Instrument Revenue	$1.6 million	Change from $1.4 million in Q3 2025 vs $1.4 million in Q3 2025 (Note: Data shows $1.4M in Q2 2025 vs $2.3M in Q2 2024, and Q3 2025 instrument revenue was $1.6M vs $1.4M in Q3 2024)

Technology validation and awareness are pushed heavily through scientific channels. Bionano Genomics reported a new quarterly record of 119 peer-reviewed publications in the second quarter of 2025, followed by 97 peer-reviewed publications in the third quarter of 2025, underscoring growing scientific acceptance. They also highlighted momentum with nine studies presented at the American Society of Human Genetics (ASHG) Meeting in Q3 2025.

The diagnostic testing services channel, operating through Bionano Laboratories (Lineagen), has seen a strategic change; the company discontinued clinical services revenue, which contributed $0.7 million in Q2 2024 and $2.0 million in Q4 2023. However, the OGM-based LDTs (Laboratory Developed Tests) are supported by reimbursement pathways. Specifically, the payment determination for the Category I CPT code 81195 for hematologic malignancies, effective January 1, 2025, was set at $1263.53. This is defintely a key enabler for clinical adoption.

• OGM systems installed base reached 384 systems as of Q3 2025 end.
• The company plans to install between 25 and 30 new OGM systems in full year 2025, exceeding prior guidance.
• The company raised $10 million in a public stock offering in September 2025.

Bionano Genomics, Inc. (BNGO) - Canvas Business Model: Customer Segments

You're looking at the core groups Bionano Genomics, Inc. (BNGO) serves as of late 2025, based on their Q3 2025 performance and strategic focus. The shift is clearly toward driving utilization from established users.

Academic and government research institutions focused on genomics and genetic disease.

This segment is evidenced by the scientific output Bionano Genomics supports. In the third quarter of 2025, the company saw 97 new peer-reviewed publications featuring their Optical Genome Mapping (OGM) technology. Furthermore, 841 human clinical research genomes were published using OGM during that quarter, which was an 84% increase compared to the third quarter of 2024. Research focus areas included constitutional disease, mosaicism, and oncology applications.

Clinical laboratories adopting OGM for cytogenomic analysis, especially in oncology.

Clinical adoption is being catalyzed by reimbursement milestones. For OGM use in cytogenomic genome-wide analysis for constitutional genetic disorders, the Centers for Medicare & Medicaid Services (CMS) established a preliminary payment determination of $1,263.53 effective January 1, 2025. For hematologic malignancies (blood cancers), the 2026 Clinical Lab Fee Schedule (CLFS) indicates a 47% increase for CPT code 81195, raising the payment determination from $1,263.53 to $1,853.22, effective January 1, 2026. Studies presented at the American Society of Human Genetics (ASHG) Meeting in October 2025 demonstrated OGM utility in cancer biomarker analysis and acute leukemias.

Pharmaceutical and biotechnology companies for cell line stability and gene therapy development.

While specific revenue figures for this segment aren't broken out, the technology's application in cancer research, such as the comparison of OGM to targeted RNA-sequencing in acute leukemias, shows direct relevance to drug development and validation pipelines within pharma and biotech.

Routine-use customers who account for over 80% of consumables revenue.

Bionano Genomics, Inc. is strategically focused on driving utilization from its existing base of routine users. Consumables and software revenues, which are the primary driver of utilization, accounted for $5.3 million of the total $7.4 million revenue in Q3 2025. This represented a 15% increase year-over-year for this category. The company sold 8,390 nanochannel array flowcells in Q3 2025, a 7% increase over the prior year. The total installed base supporting these routine uses reached 384 systems at the end of Q3 2025.

Early adopters in new regions like Japan leveraging OGM for complex genetics.

The CEO noted seeing strong momentum and expanding utilization in new regions, specifically mentioning Japan, where researchers are using OGM to address complex genetics questions.

Here's a quick look at the key Q3 2025 operational and financial metrics tied to these customer activities:

Metric	Value	Context
Total Revenue (Q3 2025)	$7.4 million	Total revenue for the three months ended September 30, 2025.
Consumables & Software Revenue (Q3 2025)	$5.3 million	Revenue from consumables and software in Q3 2025.
Consumables & Software Revenue Growth (YoY)	15%	Increase in consumables and software revenues in Q3 2025 versus Q3 2024.
Flowcells Sold (Q3 2025)	8,390	Nanochannel array flowcells sold in Q3 2025.
Total Installed Base (Q3 2025 End)	384 systems	Total OGM systems installed at the end of Q3 2025.
New OGM Systems Installed (Q3 2025)	7	Number of new OGM systems installed during Q3 2025.
Peer-Reviewed Publications (Q3 2025)	97	Number of peer-reviewed publications in the third quarter.
Clinical Research Genomes Published (Q3 2025)	841	Human clinical research genomes published using OGM in Q3 2025.
CPT Code 81195 Payment (Effective Jan 1, 2026)	$1,853.22	CMS 2026 CLFS payment determination for hematologic malignancy analysis.

The company's strategic emphasis is on the recurring revenue from these users, as evidenced by the 15% growth in consumables and software revenue, which is the core of their transformed business model.

You should review the full Q3 2025 filing to see if the company provided a specific percentage breakdown of revenue derived from the routine user segment versus new system sales, as the $5.3 million from consumables/software is a strong indicator of this segment's importance. Finance: draft 13-week cash view by Friday.

Bionano Genomics, Inc. (BNGO) - Canvas Business Model: Cost Structure

You're looking at the cost side of Bionano Genomics, Inc. (BNGO)'s operations as of late 2025, focusing on where the cash is going to support the Optical Genome Mapping (OGM) platform. The story here is one of significant cost discipline driving margin expansion, even as they invest in the platform.

The primary cost drivers revolve around developing the OGM platform and its associated consumables. High R&D expenses for OGM platform and software development remain a foundational cost, necessary to advance the technology that underpins the entire value proposition. While specific R&D dollar amounts aren't broken out in the latest reports, the overall focus on software utilization suggests continued investment in that area.

Significant cost of goods sold (COGS) exists for manufacturing instruments and flowcells, which is directly reflected in the gross margin performance. The strategic shift toward consumables and software is clearly impacting this cost structure positively. Consumables and software revenues accounted for 72% of product revenue in Q3 2025, a mix that carries a higher margin profile than instrument sales.

The commitment to cost-saving initiatives is evident in the operating expense reduction. Non-GAAP operating expenses were reduced to $9.7 million in Q3 2025. This represents a 40% year-over-year decrease from the $16.1 million reported in Q3 2024. Honestly, that kind of reduction shows a real focus on operational efficiency.

The structure supporting the commercialization efforts-Sales, General, and Administrative (SG&A) costs for a global commercial team-is bundled within the total operating expenses. Furthermore, costs associated with intellectual property protection and regulatory compliance are ongoing, necessary expenditures for a medical technology company operating globally, though these are not itemized separately in the public summaries.

Here's a quick look at the key financial metrics reflecting this cost structure management through Q3 2025:

Metric	Q3 2025 Value	Comparison/Context
Non-GAAP Operating Expenses	$9.7 million	Represents a 40% reduction year-over-year from $16.1 million in Q3 2024.
Non-GAAP Gross Margin	46%	Material improvement from 26% in Q3 2024.
Total Revenue	$7.4 million	Up 21% compared to Q3 2024.
Flowcells Sold	8,390 units	A record, showing a 7% increase over Q3 2024.
Consumables and Software Revenue Growth	15% increase	Year-over-year growth, contributing to the higher gross margin mix.

The shift in revenue mix is a direct cost-structure lever. You can see the impact:

• Consumables and software mix was 72% of product revenue in Q3 2025.
• Instrument revenue was $1.6 million in Q3 2025.
• Instrument revenue in Q3 2024 was $1.4 million.

The company is definitely prioritizing utilization over aggressive system placement, which changes the nature of their COGS and associated costs.

Finance: draft the full 2025 projected OpEx breakdown based on the Q3 run-rate by Friday.

Bionano Genomics, Inc. (BNGO) - Canvas Business Model: Revenue Streams

You're looking at how Bionano Genomics, Inc. (BNGO) brings in money, which is shifting more toward recurring revenue streams from existing users. The strategy is definitely focused on utilization now, not just putting boxes in the door.

The full-year 2025 revenue guidance remains projected to be between $26.0 million and $30.0 million. This outlook is supported by the company's focus on driving utilization within its existing installed base of Optical Genome Mapping (OGM) systems.

The revenue streams are segmented across four main areas, with a clear emphasis on the consumables and software components, which are higher margin.

For the third quarter of 2025, total revenue was $7.4 million, a 21% increase compared to the third quarter of 2024. This performance reflects the strategic shift, as prior periods included revenue from clinical services which have since been discontinued. The core business, excluding those discontinued services, saw growth.

Here's a breakdown of the revenue components based on the latest reported quarter:

Revenue Component	Q3 2025 Amount (Approximate)	Q3 2024 Amount	Year-over-Year Change (Consumables/Software)
Consumables and Software Revenue	$5.3 million	N/A	15% increase
Instrument Revenue	$1.6 million	$1.4 million	N/A
Total Revenue	$7.4 million	$6.1 million	21% increase (Total)

The consumables revenue stream is directly tied to the use of the installed base of OGM systems. You can see the volume growth in the key consumable:

• Nanochannel array flowcells sold in Q3 2025 totaled 8,390 units, which was a 7% increase from Q3 2024.
• Consumables and software together represented 72% of the product mix in Q3 2025.

Instrument revenue comes from the sale of OGM systems, such as Saphyr/Stratys. The company is actively managing the installation pace, with expectations now raised for the full year. The installed base stood at 384 systems at the end of Q3 2025, following 7 new installations during that quarter. The expectation for new OGM system installations for the full year 2025 is set to surpass 25 systems, an increase from previous guidance of 20 to 25.

Service revenue is derived from instrument maintenance contracts and OGM data services, though the company has moved away from clinical services revenue. The focus on routine users is intended to generate more predictable, recurring revenue from the consumables and software.

Software revenue from licenses and subscriptions for VIA™ and Solve™ is bundled with the consumables growth, as consumables and software sales are reported together and showed a 15% year-over-year increase in Q3 2025.

Finance: draft 13-week cash view by Friday.